Prostate Cancer VL

ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer - Andrew Laccetti

Details
Zach Klaassen discusses the ARAMON trial with Andrew Laccetti, which focuses on the impact of enzalutamide and darolutamide on testosterone levels in patients with high-risk nonmetastatic hormone-sensitive prostate cancer. Dr. Laccetti emphasizes the critical need for treatments that not only enhance cancer outcomes but also minimize side effects and improve quality of life for men undergoing long...

The De-Escalate Trial: Intermittently Stopping Prostate Cancer Treatments to Improve Quality of Life - Guillaume Grisay

Details
Guillaume Grisay introduces the De-Escalate trial, a study focused on intermittent treatment for metastatic hormone-naive prostate cancer patients who have achieved a deep PSA response after induction therapy. This innovative approach aims to preserve overall survival while improving patients' quality of life by pausing ADT and AR pathway inhibitors, addressing the challenges of chronic toxicities...

Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova

Details
Tanya Stoyanova discusses research on Trop2's role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study reveals Trop2 as a high-potential therapeutic target due to its overexpression in various epithelial cancers, including prostate cancer, where it's linked to aggressive behavior. Their work, validated in a large patient cohort...

High-Risk Prostate Cancer: 80Gy + ADT Extends Survival Without Added Toxicity - Christophe Hennequin

Details
Leslie Ballas and Christophe Hennequin explore the findings of the GETUG-AFU 18 randomized trial, which evaluated the impact of radiotherapy dose escalation in high-risk prostate cancer patients receiving long-term androgen deprivation therapy (ADT). Conducted between 2009 and 2013, the trial randomized 500 patients to receive either 70 Gy or 80 Gy, revealing significant improvements in progressio...

The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian

Details
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...

Highlighting APCCC 2024: An International Prostate Cancer Meeting - Silke Gillessen & Aurelius Omlin

Details
Alicia Morgans hosts a discussion with Professors Silke Gillessen and Aurelius Omlin about the upcoming APCCC 2024, emphasizing its significance for the prostate cancer community. The congress invites all interested in prostate cancer management, offering a blend of clinical and translational research insights. The conversation also touches on the congress's inclusivity, encouraging participation...

Addressing the Intersection of Climate Change and Cancer: A Roadmap to Action for Urological Care Providers - Alexander Cole

Details
Zach Klaassen and Alexander Cole discuss the impact of climate change on cancer screening, highlighting a study that explores public awareness of climate change's health impacts and its association with cancer risk attitudes. Utilizing the HINTS database, they found a correlation between concern for climate change and interest in cancer screening, suggesting that awareness of environmental health...

Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone

Details
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...

Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt

Details
Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...

Prostate Cancer Cell Metabolism Dictates Differentiation and Therapy Response - Andrew Goldstein

Details
Andrea Miyahira hosts Andrew Goldstein to discuss his group's research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including grad students Jenna Giafaglione and Preston Crowell, explores the metabolic processes influencing prostate cancer's response to anti-androgen treatment. Their study reveals that basal and luminal cells in the prostate have distin...